Arcus Biosciences, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$247M
R&D
$523M
D&A
$10M
Operating Income
$-386M
EBITDA
$-376M
Interest Expense
$9M
Other Income/Expense
$42M
Pretax Income
$-353M
Tax Provision
$0
Net Income
$-353M
Operating Margin
-156.3%
Net Margin
-142.9%
Effective Tax Rate
0.0%
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$412M
Tax Credit Carryforwards
$59M
NOL Carryforwards
—
ETR (Continuing Operations)
0.1%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.1%
Operating Lease Cost
$17M
Revenue YoY Variation
-4.3%
Income YoY Variation
-17.0%